A promising treatment for type 1 diabetes
This year, we celebrate the 100th anniversary of a revolution for diabetic patients: the discovery of insulin. But what if another revolution were just around the corner? The development of an effective technique for transplanting the cells responsible for insulin production could lead to a long-term treatment for type 1 diabetes.
Insulin-producing cell transplantation has been performed since the mid-1980s. This procedure aims to restore insulin production in diabetic patients, allowing them to become independent of insulin injections. However, they still need to take anti-rejection medication, which comes with its share of side effects. A solution has been developed to reap the benefits without the negative effects of anti-rejection drugs. Some research teams are considering "hiding" the insulin-producing cells from the immune system using a protective capsule.

To protect these cells, an engineering solution can be used: 3D bioprinting. The team of Paul de Vos, professor in the Department of Pathology and Medical Biology at the University of Groningen in the Netherlands, presented in a recent study a capsule made with their own proprietary biological ink. Their goal: to overcome the problems of other biological inks, namely print quality, mechanical stability, and biological compatibility.
The capsule is made from alginate, a biomaterial derived from brown algae. Alginate is already known for its ability to ensure the survival and growth of transplanted cells. The team is innovating by proposing the addition of two compounds: pectin and Pluronic F127. According to their study, this capsule could ensure the long-term survival of transplanted cells for the treatment of type 1 diabetes.
Indeed, adding pectin to their capsule reduces the inflammatory response. Pluronic F127, meanwhile, increases the printing capacity of the bio-ink. This compound also leads to the formation of micropores in the capsule. These tiny pores allow for the exchange of nutrients and waste products. Their small size also prevents the entry of immune cells that could attack the newly transplanted cells.

In addition to optimizing the composition of their capsule, Professor Devos's team optimized its structure: it is grid-shaped. This design promotes the exchange of oxygen and nutrients for the cells hidden inside the capsule. Furthermore, the capsule's immunomodulatory capabilities help reduce the formation of scar tissue. Thus, should the capsule ever need to be replaced, this could be done more easily.
Type 1 diabetes is an autoimmune disease, explains Dr. Steven Paraskevas, a transplant surgeon at the McGill University Health Centre and associate professor in the Department of Surgery at McGill University: “For an unknown reason, the immune system attacks the insulin-producing cells in the pancreas, which is the main organ responsible for controlling sugar metabolism.” The insulin-producing cells are thus destroyed. However, the human body needs insulin to allow sugar, the body's energy source, to enter the cells. Currently, not all patients are eligible for an insulin-producing cell transplant.
Mr. Gagnon* has lived with type 1 diabetes since his early twenties. He is now a proud grandfather. For him, diabetes comes with a mental burden: “Everything has to be planned in advance. For example, if we go for a hike or a run, we need a little planning . I have to calculate my carbohydrate intake and my injections have to be adjusted accordingly. Spontaneity is more difficult.” However, Mr. Gagnon is aware of how fortunate he is. His diabetes is easily manageable, which isn't the case for all patients.
Some people with diabetes struggle to adequately control their blood sugar: they have what is called unstable diabetes. These are the patients who are candidates for insulin-producing cell transplantation. Many aspects of this new technology still need improvement, but the results are encouraging. "The idea of combining an engineered solution with a biological one is very interesting. It's something to keep an eye on, but we may have to wait a few more years. [...] We are at a crossroads" says Dr. Paraskevas.
* Fictitious name to protect medical confidentiality.
This web dossier was produced as part of the COM-6060 course (microprogram in Journalism and Scientific Communication at Laval University).




Comments